| Institution: | 1. Department of Obstetrics and Gynaecology, Radboud Institute for Molecular Life Sciences, Radboud university medical center, Nijmegen, The Netherlands;2. Department of Obstetrics and Gynaecology, Catharina Hospital, Eindhoven, The Netherlands;3. Department of Biostatistics, Radboud Institute for Health Sciences, Radboud university medical center, Nijmegen, The Netherlands;4. Department of Medical Microbiology, Radboud university medical center, Nijmegen, The Netherlands;5. Department of Obstetrics and Gynaecology, Radboud university medical center, Nijmegen, The Netherlands;6. Department of Pathology, Radboud university medical center, Nijmegen, The Netherlands
PALGA, The Nationwide Network and Registry of Histo- and Cytopathology, Houten, The Netherlands |
| Abstract: | Women with cervical intraepithelial neoplasia grade 3 (CIN3) have a long-lasting increased risk for noncervical high-risk human papillomavirus (hrHPV)-related (pre)malignancies. The aim of our study was to estimate this risk in women with recurrent CIN3 compared to women without a history of CIN3 and women with a single episode of CIN3. Women with a CIN3 diagnosis between 1990 and 2010 were obtained from the Dutch Pathology Registry (PALGA) and matched with a control group of women without CIN3. Analysis has been conducted in a subset of women with recurrent CIN3, defined as reoccurrence minimally 2 years post-treatment. Cases of noncervical hrHPV-related (pre)malignancies of the anus, vulva, vagina and oropharynx were identified until 2015 and incidence rate ratios (IRRs) were estimated. Then, 1,797 women with recurrent CIN3 were included with a median age of 34 years (range 18–76) and 31,594 person-years of follow-up. Women with recurrent CIN3 had an increased risk of developing noncervical hrHPV-related (pre)malignancies compared to women without CIN3 with an IRR of 25.96 (95%CI 6.32–106.58). The IRR was 2.48 (95% CI 1.87–3.30) compared to women with a single episode of CIN3. Studies on posttreatment follow-up and prophylactic hrHPV vaccination are warranted. |
